Building on the Promise of Resolution Pharmacology for Novel Disease Modifying Therapies

Thetis Pharmaceuticals LLC is building on the promise of resolution pharmacology by applying its unique capabilities to develop innovative small molecule drugs for treatment of diseases with underlying inflammation. Our drug candidates deliver specialized proresolving mediators (SPMs) that are the endogenous counterparts to the proinflammatory leukotrienes and prostaglandins. Experimental models of acute and chronic inflammatory diseases have established that these mediators regulate the resolution of inflammation, protect organs, and promote tissue repair and regeneration.

Using our HEALER™ platform technology, we create novel derivatives of SPMs and long chain polyunsaturated fatty acids. One lead drug candidate is TP-252 for management of polyp burden in young patients with familial adenomatous polyposis or FAP, a rare genetic disease that causes proliferation of polyps during adolescence requiring prophylactic colectomy at a young age to reduce risk of colorectal cancer. Thetis has received orphan drug designation for TP-252 for treatment of FAP from the FDA Office of Orphan Products Development.

Beyond TP-252, we are developing TP-6211, a novel derivative of protectin DX for management of severe postoperative ileus, a debilitating cessation of GI motility following abdominal surgery that results in significant surgical co-morbidities and increased length of hospital stay. Other SPM-based development candidates with potential application in disease targets where SPMs have shown strong proresolution effects are also under consideration.

Learn more about our HEALER platform. »»